Potentiation and Mechanism of Berberine as an Antibiotic Adjuvant Against Multidrug-Resistant Bacteria

Hongjuan Zhou, Wenli Wang, Long Cai, Tingting Yang

Clinical Laboratory Experiment Center, Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China

Correspondence: Tingting Yang; Long Cai, Clinical Laboratory Experiment Center, Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, No. 208 East Huancheng Road, Hangzhou, 310003, People’s Republic of China, Email yang1989tingting@126.com; cailong317@hotmail.com

Abstract: The growing global apprehension towards multi-drug resistant (MDR) bacteria necessitates the development of innovative strategies to combat these infections. Berberine (BER), an isoquinoline quaternary alkaloid derived from various medicinal plants, has surfaced as a promising antibiotic adjuvant due to its ability to enhance the effectiveness of conventional antibiotics against drug-resistant bacterial strains. Here, we overview the augmenting properties and mechanisms of BER as an adjunctive antibiotic against MDR bacteria. BER has been observed to exhibit synergistic effects when co-administered with a range of antibiotics, including β-lactams, quinolones, aminoglycosides, tetracyclines, macrolides, lincosamides and fusidic acid. The adjunctive properties of BER led to an increase in antimicrobial effectiveness for these antibiotics against the corresponding bacteria, a decrease in minimal inhibitory concentrations, and even the reversal from resistance to susceptibility sometimes. The potential mechanisms responsible for these effects included the inhibition of antibiotic efflux, the disruption of biofilm formation, the modulation of host immune responses, and the restoration of gut microbiota homeostasis. In brief, BER demonstrated significant potential as an antibiotic adjuvant against MDR bacteria and is a promising candidate for combination therapy. Further research is necessary to fully elucidate its mechanism of action and address the challenges associated with its clinical application.

Keywords: berberine, antibiotic adjuvant, multidrug-resistant bacteria, efflux pump, biofilm

Introduction

Antimicrobial resistance (AMR) poses a significant threat to human, animal and environmental health, as well as the global economy and development.1 It was reported that an estimated 4.95 million deaths were associated with bacterial AMR in 2019, including 1.27 million deaths directly attributable to bacterial AMR.2 The Review on Antimicrobial Resistance, commissioned by the UK Government, has warned that AMR could result in the deaths of 10 million people annually by 2050.3 The widespread utilization, overuse and inappropriate use of antimicrobials has resulted in the proliferation of antimicrobial resistance over the past eighty years.4 The escalating global prevalence of drug-resistance renders antibiotics progressively ineffective. The absence of effective measures for the prevention and appropriate management of drug-resistant infections, coupled with insufficient accessibility to both novel and established antimicrobial agents that meet quality standards, will result in a surge in the population of individuals experiencing treatment failure or succumbing to infectious diseases.5 Consequently, there is an urgent requirement for novel antibacterial agents or a new medication regimen.

Antibiotic adjuvants present a viable and complementary strategy to the discovery of novel antibiotics and the optimization of current ones.6 These adjuvants, which may include compounds or herbal products, do not possess direct bactericidal properties but rather augment antibiotic efficacy through various mechanisms such as resistance blockade,
intracellular antibiotic accumulation enhancement, complementary bactericidal pathways, signaling and regulatory pathway inhibition or boosting the host response to bacterial infection. Berberine (BER), an isoquinoline quaternary alkaloid, has been extracted from several medicinal plants, including *Hydrastis canadensis, Berberis aristata, Coptis chinensis, Coptis rhizome, Coptis japonica, Phellodendron amurense*, and *Phellodendron chinense* schneid. It gained more attention as a potential adjuvant of antibiotics against multi-drug resistant (MDR) bacterial antibiotics recently. BER effectively reduced the minimum inhibitory concentrations (MICs) and enhanced bactericidal activity of some antibiotics against MDR bacteria, as well as inhibiting of bacterial adhesion and intracellular invasion. This review summarizes the synergistic effects and underlying mechanisms observed when BER was used in combination with conventional therapeutic antibiotics against MDR bacteria.

**The History and Medicinal Lineage of BER**

BER is the primary bioactive compound in the traditional Chinese medicinal herb *Huanglian*. *Huanglian* is a widely utilized Chinese herb that has long history of medicinal use. The earliest documented mention of *Huanglian* dates back to the “Shen Nong Ben Cao Jing”, which was written in 200 A.D. In “Note of Elite Physicians”, Hongjing Tao was the first to document the anti-diabetic effects of *Huanglian* around 1500 years ago.

Modern pharmacological research has demonstrated that BER exhibits inhibitory effects on a broad range of Gram-positive and Gram-negative bacteria, rendering it effective in treating gastrointestinal infections and bacterial dysentery. Subsequent research on the pharmacological effects and mechanisms of BER has revealed its additional activities, including anti-tumor, cardiovascular protection, anti-inflammatory and anti-Alzheimer’s disease effects. Consequently, it has achieved broad application in the management of gastrointestinal disorders, infectious diseases and specific tumors.

**The Structure and Pharmacological Attributes of BER**

The chemical structure of BER consists of a fused ring system of dihydroisoquinoline and isoquinoline, exhibiting notable planar characteristics (Figure 1). The skeleton can be categorized into four rings, denoted as A, B, C and D. In the A ring, the C2 and C3 positions form a methylenedioxy group. The C ring features a quaternary ammonium structure, wherein a positively charged nitrogen atom resides in the aromatic ring. This quaternary ammonium structure is essential for the antibacterial activity of BER. The D ring is marked by the attachment of a methoxy group to both the C9 and C10 positions.

The main clinical application of BER is its hydrochloride salt, administered orally. However, pharmacokinetic studies have shown that BER has low oral bioavailability and intestinal absorption rates, measuring less than 5%. This may be partly attributed to the presence of the strong hydrophilic quaternary ammonium group in the structure, impeding

![Figure 1](https://example.com/berberine-structure.png)
the transmembrane transport and intestinal absorption of BER.\textsuperscript{26} Furthermore, hepatic and biliary excretion, self-aggregation and interaction with the P-glycoprotein pump may also contribute to the limited bioavailability.\textsuperscript{16} Various strategies have been developed to enhance the bioavailability of berberine, including co-administration with other substances or the use of lipid nanoparticles for BER delivery.\textsuperscript{27}

The BER metabolism occurs in two stages. Phase I metabolism includes demethylation, demethylation and reduction, leading to the formation of multiple metabolites including berberrubine (M1), thalifendine (M4), demethylneberberine (M2), hydroxylated berberine, jatrorrhizine (M3), columbamine isomer and dibberberine. In the subsequent phase, BER is subjected to glucuronidation and sulfation, resulting in the formation of Phase II metabolites, which are subsequently excreted through bile and urine. BER metabolism can take place in the liver, intestine and gastrointestinal microbiota. However, the liver serves as the primary site of metabolism.\textsuperscript{27}

Several studies have indicated that BER exhibits low toxicity in the human body. Phase I clinical trials have demonstrated the safety of consuming excessive amounts of BER. BER has minimal toxicity towards healthy cells. While BER may induce adverse reactions such as constipation or nausea, they are typically not severe. Ceasing BER use leads to the disappearance of the most common constipation symptoms.\textsuperscript{28}

**The Synergistic Effect of BER on Antibiotics**

Combining antibiotics was a commonly employed tactic by clinicians to combat MDR bacteria or multiple infections. The potent synergy between the constituents of the combination presented an opportunity to rejuvenate existing antibiotics.\textsuperscript{29,30} The quantification of synergy could be achieved through the implementation of the straightforward checkerboard strategy, which involved the systematic dilution of concentrations of both agents to determine the optimal concentrations that result in the most effective interaction. The fraction inhibitory concentration index (FICI) was a mathematical tool utilized to determine the interaction between two compounds, A and B. The FICI was calculated using the formula FICI = MIC (A when combination with B)/MIC (A alone) + MIC (B when combination with A)/MIC (A alone). The FICI ≤0.5 indicates a synergistic effect, 0.5< FICI ≤1 indicating an additive effect, 1< FICI ≤2 indicating an indifference, and FICI >2 indicates antagonism.\textsuperscript{31,32} In cases where adjuvants do not have measurable MIC, the concentration of the adjuvant that reduces MIC of the combined antibiotic fourfold is a reliable indicator of potency. What is more significant is the degree of adjuvant concentration that reduces the MIC of antibiotics in resistant bacteria to a level equivalent to or below the breakpoint concentration.\textsuperscript{32}

We used the aforementioned approaches for assessing the effectiveness of BER as an adjuvant in combination with other antibiotics against clinically prevalent MDR bacteria, encompassing gram-negative bacteria (eg, *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, *Salmonella* and *Klebsiella pneumoniae*), gram-positive bacteria (eg, *Methicillin-resistant Staphylococcus aureus* and *Clostridium difficile*), and non-tuberculous mycobacteria (eg, *Mycobacterium avium* complex and *Mycobacterium abscessus*).

**Gram-Negative Bacteria**

The World Health Organization (WHO) released a list of bacteria that require urgent development of new antibiotics in 2017. The list specifically emphasized the danger posed by gram-negative bacteria that exhibit resistance to multiple antibiotics. Notably, all bacterial strains categorized as “Priority Critical” were carbapenem-resistant gram-negative bacteria, which encompass carbapenem-resistant *A. baumannii*, carbapenem-resistant *P. aeruginosa* and third-generation cephalosporin-resistant *Enterobacteriaceae*.\textsuperscript{33} Based on the recent national bacterial resistance surveillance data from China, it has been observed that approximately 70% of clinical isolates resistant to antibiotics were gram-negative bacteria.\textsuperscript{34} The treatment of infections caused by such bacteria poses a significant challenge for medical practitioners.\textsuperscript{35} There was a growing gap between the clinical need for new antibiotics and new drug discovery and development. The unique impermeable outer membrane barriers hindered the discovery of effective antibiotics against gram-negative bacteria.\textsuperscript{36} Consequently, there existed a pressing necessity for novel antibiotics and alternative approaches to combat infections of this nature. Recent research has demonstrated that BER can enhance the efficacy of conventional therapeutic antibiotics against MDR gram-negative bacteria, including *P. aeruginosa*, *A. baumannii*, *Salmonella* and *K. pneumoniae* (Tables S1–S3). These findings offered crucial insights for the management of infections caused by such bacteria.
**P. aeruginosa**

A variety of antibiotics, including β-lactam/β-lactamase inhibitor combinations, carbapenems, fluoroquinolones and/or aminoglycosides, have been conventionally utilized as the preferred treatment options against resistant *P. aeruginosa* isolates responsible for infections.\(^\text{37}\) Furthermore, the macrolide antibiotic azithromycin was frequently administered in combination with the aforementioned drugs to treat biofilm-associated cystic fibrosis infections caused by *P. aeruginosa*.\(^\text{38,39}\) However, the emergence of MDR and extensively drug-resistant (XDR) organisms has diminished the efficacy and reliability of these antibiotics.\(^\text{37}\)

BER has been reported to exhibit synergistic effects with the carbapenem antibiotic imipenem, the macrolide antibiotic azithromycin, and several aminoglycoside antibiotics in in vitro susceptibility tests against MDR or XDR *P. aeruginosa* (Tables 1 and S1). The FICI of BER combining with imipenem was 0.375. The addition of 1/4 MIC BER (128μg/mL) resulted in 8-fold reduction of the MIC of *P. aeruginosa* to imipenem. The combination of BER and azithromycin showed an FICI of 0.13–0.5 and led to a 4–16-fold reduction in MICs to azithromycin under 128μg/mL of BER. In the infection model, there was a marked increase in mice survival and a great improvement in the inflammation of infected lungs at 0.8 mg/kg of azithromycin combined with 3.2 mg/kg of BER.\(^\text{40}\) For aminoglycoside antibiotics, such as amikacin, arbekacin, gentamicin and tobramycin, the combination of BER led to a 2~8-fold reduction in MICs when combating MDR *P. aeruginosa*.\(^\text{41}\) However, the efficacy of the combination of BER and tobramycin varies among different strains. Compared to the administration of tobramycin alone, the co-administration demonstrated a twofold increase in inhibitory activity and a two to four logarithmic increase in killing activity against 13 of the 28 *P. aeruginosa* clinical isolates tested. However, no synergistic effects were observed in the remaining strains.\(^\text{42,43}\) In conclusion, BER exhibited significant potential in reducing the resistance of imipenem, azithromycin, amikacin, arbekacin and gentamicin against MDR/XDR *P. aeruginosa*. Nonetheless, the extent of reduction in tobramycin resistance varies depending on the strains.

**A. baumannii**

Numerous strains of MDR *A. baumannii* have demonstrated resistance to clinically significant antibiotics, including ceftazidime/avibactam, ampicillin/sulbactam, and piperacillin/tazobactam.\(^\text{55,56}\) BER, when used alone, exhibits limited antibacterial activity against MDR *A. baumannii*, with a MIC range of 256 to 1024 μg/mL (Table S1).\(^\text{45}\) However, the combination of BER with other antibiotics has been shown to significantly decrease the MICs of MDR *A. baumannii* (Tables 1 and S1). Synergistic effects (FICI <0.5) were observed in the combinations of BER/sulbactam and BER/meropenem for the MDR strains. The addition of BER even resulted in the re-sensitization of MDR strains to various antibiotics, including ciprofloxacin (MIC reduced from 32 to 1 μg/mL), sulbactam (MIC reduced from 64 to 4 μg/mL), and meropenem (MIC reduced from 128 to 2 μg/mL). In a murine infection model, the combination therapy of 20 mg/kg BER and 400 mg/kg sulbactam exhibited superior antimicrobial efficacy against MDR strains when compared to monotherapy.\(^\text{45}\) This observation highlighted the potential of BER to reverse antibiotic resistance or augment the susceptibility of MDR *A. baumannii* to multiple antibiotics that have lost their effectiveness. The utilization of BER as an adjuvant presented a promising approach to reintroduce off-the-treatment-list antibiotics, such as sulbactam and ciprofloxacin, for the treatment of MDR *A. baumannii* infections.

**Salmonella**

*Salmonella* spp. remains a significant bacterial pathogen responsible for foodborne illnesses. The FDA has approved three antibiotics, namely ciprofloxacin, ceftriaxone and azithromycin, for the treatment of *Salmonella* infections in the United States.\(^\text{57}\) However, resistance to these antibiotics has become increasingly prevalent in recent years, particularly in Asia. It was noteworthy that the escalation in the rate of ciprofloxacin resistance was evident across all serotypes of *Salmonella*.\(^\text{57,58}\) The co-administration of BER and ciprofloxacin exhibited an additive effect against MDR *Salmonella*, with an FICI of 0.75 (Tables 1 and S1). The MIC to ciprofloxacin was reduced by 4-fold (from 2.56 to 0.64 μg/mL), transitioning from resistant to an intermediate level (Table S1).\(^\text{46}\) This combination therapy may reduce the dosage of ciprofloxacin required for treatment, conferring the advantage of preventing drug resistance and minimizing adverse effects.
### Table 1  The Effect of Sub-MIC Berberine on Antibiotics Against Common Multidrug-Resistant Bacteria

<table>
<thead>
<tr>
<th>Bacteria Stains</th>
<th>Antibiotic</th>
<th>No. of Strains*</th>
<th>Fold Decrease</th>
<th>&lt;4 Fold Decrease (No.)</th>
<th>≥4 Fold Decrease (No.)</th>
<th>Unknown</th>
<th>FICI</th>
<th>Synergism (No.)</th>
<th>Additivity (No.)</th>
<th>Indifference (No.)</th>
<th>Antagonism (No.)</th>
<th>Unknown (No.)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gram-negative bacteria</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P. aeruginosa</td>
<td>IMP</td>
<td>1</td>
<td>8</td>
<td>1</td>
<td>0.38</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[44]</td>
<td></td>
</tr>
<tr>
<td>P. aeruginosa</td>
<td>TOB</td>
<td>33</td>
<td>1~16</td>
<td>17</td>
<td>16</td>
<td>0.31~1.25</td>
<td>13</td>
<td>13</td>
<td>7</td>
<td></td>
<td></td>
<td>[42]</td>
<td></td>
</tr>
<tr>
<td>P. aeruginosa</td>
<td>TOB</td>
<td>3</td>
<td>2~8</td>
<td>1</td>
<td>2</td>
<td>0.31~0.75</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>[41]</td>
<td></td>
</tr>
<tr>
<td>P. aeruginosa</td>
<td>ABK</td>
<td>3</td>
<td>8</td>
<td>3</td>
<td>0.12</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[41]</td>
</tr>
<tr>
<td>P. aeruginosa</td>
<td>AMK</td>
<td>3</td>
<td>4~8</td>
<td>3</td>
<td>0.38~0.5</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[41]</td>
</tr>
<tr>
<td>P. aeruginosa</td>
<td>GEN</td>
<td>3</td>
<td>4</td>
<td>3</td>
<td>0.13~0.25</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[41]</td>
</tr>
<tr>
<td>P. aeruginosa</td>
<td>AZM</td>
<td>10</td>
<td>4~16</td>
<td>10</td>
<td>0.06~0.25</td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[40]</td>
</tr>
<tr>
<td>A. baumannii</td>
<td>MEN</td>
<td>4</td>
<td>8~64</td>
<td>4</td>
<td>0.27~0.63</td>
<td>3</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[45]</td>
</tr>
<tr>
<td>A. baumannii</td>
<td>SUL</td>
<td>4</td>
<td>2~8</td>
<td>1</td>
<td>3</td>
<td>0.31~0.75</td>
<td>3</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[45]</td>
</tr>
<tr>
<td>A. baumannii</td>
<td>CIP</td>
<td>4</td>
<td>8~32</td>
<td>4</td>
<td>0.28~1.13</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[45]</td>
</tr>
<tr>
<td>A. baumannii</td>
<td>TGC</td>
<td>4</td>
<td>2~16</td>
<td>1</td>
<td>3</td>
<td>0.56~0.75</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salmonella</td>
<td>CIP</td>
<td>1</td>
<td>4</td>
<td>1</td>
<td>0.75</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>K. pneumoniae</td>
<td>CIP</td>
<td>20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gram-positive bacteria</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRSA</td>
<td>AMP</td>
<td>1</td>
<td>4</td>
<td>1</td>
<td>0.63</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[48]</td>
</tr>
<tr>
<td>MRSA</td>
<td>OXA</td>
<td>1</td>
<td>8</td>
<td>1</td>
<td>0.50</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRSA</td>
<td>AZM</td>
<td>10</td>
<td>4~16</td>
<td>10</td>
<td>0.19~0.63</td>
<td>9</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[49]</td>
</tr>
<tr>
<td>MRSA</td>
<td>LEV</td>
<td>10</td>
<td>2~8</td>
<td>1</td>
<td>9</td>
<td>0.38~0.75</td>
<td>9</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRSA</td>
<td>CLI</td>
<td>15</td>
<td>2~32</td>
<td>1</td>
<td>13</td>
<td>1</td>
<td>0.16~0.75</td>
<td>12</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRSA</td>
<td>RIF</td>
<td>15</td>
<td>16~64</td>
<td>14</td>
<td>1</td>
<td>0.27~0.52</td>
<td>13</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRSA</td>
<td>FA</td>
<td>30</td>
<td>1~8</td>
<td>22</td>
<td>8</td>
<td>0.19~2.00</td>
<td>6</td>
<td>15</td>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. difficile</td>
<td>VAN</td>
<td>9</td>
<td>1~32</td>
<td>3</td>
<td>6</td>
<td>0.56~1.50</td>
<td>8</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
Table 1 (Continued).

<table>
<thead>
<tr>
<th>Bacteria Stains</th>
<th>Antibiotic</th>
<th>No. of Strains&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Fold Decrease</th>
<th>&lt;4 Fold Decrease (No.)</th>
<th>≥4 Fold Decrease (No.)</th>
<th>Unknown</th>
<th>FICI</th>
<th>Synergism (No.)</th>
<th>Additivity (No.)</th>
<th>Indifference (No.)</th>
<th>Antagonism (No.)</th>
<th>Unknown (No.)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mycobacteria</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M. avium complex</td>
<td>CLA</td>
<td>12</td>
<td>2~8192</td>
<td>1</td>
<td>10</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[53]</td>
</tr>
<tr>
<td>M. abscessus</td>
<td>TMP/SXT</td>
<td>1</td>
<td>4</td>
<td>1</td>
<td>0.75</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[54]</td>
</tr>
<tr>
<td>M. abscessus</td>
<td>CLA</td>
<td>1</td>
<td>4</td>
<td>1</td>
<td>0.75</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[54]</td>
</tr>
<tr>
<td>M. abscessus</td>
<td>LZD</td>
<td>1</td>
<td>8</td>
<td>1</td>
<td>0.625</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[54]</td>
</tr>
<tr>
<td>M. abscessus</td>
<td>AMI</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[54]</td>
</tr>
<tr>
<td>M. abscessus</td>
<td>TOB</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1.5</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[54]</td>
</tr>
<tr>
<td>M. abscessus</td>
<td>DOX</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1.5</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[54]</td>
</tr>
<tr>
<td>M. abscessus</td>
<td>MIN</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1.5</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[54]</td>
</tr>
<tr>
<td>M. abscessus</td>
<td>TGC</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[54]</td>
</tr>
<tr>
<td>M. abscessus</td>
<td>IMP</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[54]</td>
</tr>
<tr>
<td>M. abscessus</td>
<td>FOX</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[54]</td>
</tr>
<tr>
<td>M. abscessus</td>
<td>FEP</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[54]</td>
</tr>
<tr>
<td>M. abscessus</td>
<td>AXO</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1.5</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[54]</td>
</tr>
<tr>
<td>M. abscessus</td>
<td>AUG</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1.5</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[54]</td>
</tr>
<tr>
<td>M. abscessus</td>
<td>CIP</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[54]</td>
</tr>
<tr>
<td>M. abscessus</td>
<td>MXF</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1.5</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[54]</td>
</tr>
</tbody>
</table>

Notes: *Only clinical strains were counted.

Abbreviations: MIC, minimum inhibitory concentrations; MRSA, methicillin-resistant Staphylococcus aureus; AMK, amikacin; ABK, arbekacin; GEN, gentamicin; AZM, azithromycin; SUL, sulbactam; TGC, tigecycline; CIP, ciprofloxacin; MEM, meropenem; AMR, ampicillin; OXA, oxacillin; LEV, levofloxacin; CL, clindamycin; RIF, rifampicin; FA, fusidic acid; VAN, Vancomycin; TMP/SXT, trimethoprim/sulfamethoxazole; CLA, clarithromycin; LZD, linezolid; IMP, imipenem; FOX, cefoxitin; CIP, ciprofloxacin; MXF, moxifloxacin; DOX, doxycycline; MIN, minocycline; AMI, amikacin; TOB, tobramycin; AUG, amoxicillin/clavulanic acid; AXO, ceftriaxone; FEP, cefepime; TGC, tigecycline.
effects. This suggests that the combination could represent a promising strategy for the management of *Salmonella* infection.

*K. pneumoniae*
A significant proportion of *K. pneumoniae* acquires resistance to multiple antimicrobials, in addition to inherently resisting penicillins. BER has been shown to enhance the susceptibility of MDR *K. pneumoniae* to ciprofloxacin, reducing the incidence of drug resistance (Tables 1 and S1). The presence of BER resulted in a 50–75% reduction in the concentration of ciprofloxacin compared to the use of ciprofloxacin alone. The combination of the two drugs was demonstrated synergistic (15%) and additive (80%) effects against most *K. pneumoniae* isolates. It significantly inhibited the growth of bacteria in the time-kill assay. These indicated that BER has potential in the development of antibiotic treatment regimens targeting MDR *K. pneumoniae*.

Gram-Positive Bacteria
Globally, treatment failure caused by gram-positive cocci infections posed a new clinical dilemma after gram-negative bacilli. WHO has recently designated gram-positive vancomycin-resistant *Enterococcus* (VRE), methicillin-resistant *Staphylococcus aureus* (MRSA), and vancomycin-resistant *Staphylococcus aureus* (VRSA) as high priority categories requiring new antimicrobial treatments. The clinical urgency for novel antimicrobial agents or effectively therapeutic strategies to address the therapeutic dilemma of gram-positive cocci were pressing. BER, when utilized as an antibiotic adjuvant, exhibits the capacity to augment the susceptibility of certain gram-positive drug-resistant bacteria to particular antibiotics, offering promising prospects for its therapeutic utilization.

MRSA
The global dissemination of MRSA has resulted in its emergence as a predominant cause of bacterial infections in healthcare and community settings. This pathogen exhibits resistance to a wide range of antibiotics, including β-lactams and cephalosporins. The addition of BER has been shown to restore the antimicrobial activity of various antibiotics against MRSA, including β-lactams (ampicillin and oxacillin), rifamycins (rifampicin), macrolides (azithromycin), lincosamides (clindamycin), and fusidic acid (Tables 1 and S2). The combination of BER and these antibiotics exhibited synergistic effects, resulting in a 2–16 folds reduction in the MICs of antibiotics against MRSA, except ampicillin. The effects of combination of BER and ampicillin vary among two studies. One study demonstrated an additive effect (FICI = 0.625) and led to 8-fold reduction in MICs to ampicillin, while the other reported indifferent effects (FICI = 1.5–2.0). This indicates the need for further research to elucidate the interaction between these two drugs. The combination of BER and the β-lactam antibiotic CFZ has not been found to yield significant results against MRSA.

*C. difficile*
Another increasingly common gram-positive MDR bacterium is *C. difficile*, which has been classified as an “Urgent” level to public health in 2019 by the Centers for Disease Control and Prevention. Clinically, *C. difficile* was responsible for causing approximately 10–25% of antibiotic-associated diarrhea, 50–75% of antimicrobial-associated colitis, and 90–100% of pseudomembranous colitis. The combination of BER and vancomycin, a peptide antibiotic, has been shown to exhibit an additive effect (FICI = 0.625–0.75) and reduced the MICs of MDR *C. difficile* to vancomycin by 4–8-fold (Tables 1 and S2).

Mycobacteria
Mycobacterial-induced pulmonary diseases have been identified as a significant contributor to morbidity and mortality in humans, such as tuberculosis caused by *Mycobacterium tuberculosis*. Recent epidemiological studies revealed that the global incidence of non-tuberculous mycobacteria (NTM) infections was on the rise, posing a new critical public health concern. Among the NTM species, *Mycobacterium avium* complex and *Mycobacterium abscessus* have been identified as the most commonly encountered pathogens. The treatment of pulmonary infections caused by NTM has always been a challenge due to the intrinsic resistance of these bacteria to many commonly used antibiotics. In particular *M. abscessus*
infections, which are resistant to most classes of antibiotics, including macrolides, aminoglycosides, rifamycins, tetracyclines and β-lactams.64

Recent studies have shown that the combination of BER with anti-NTM drugs may reduce the MICs of *M. avium* complex and *M. abscessus* to certain antibiotics, such as the frequently employed therapeutic drugs clarithromycin and linezolid. The addition of BER resulted in a reduction of the MICs of *M. avium* complex to clarithromycin by 2 to 8192-fold (median: 4-fold) (Tables 1 and S3). Some high-level clarithromycin-resistant strains even reverted to clarithromycin susceptibility or intermediate levels with MICs decreasing from 2048 to 0.25–16 μg/mL (128–8192-fold). Moreover, in clarithromycin-susceptible *M. avium* complex strains, the concomitant use of BER also demonstrated a synergistic effect, resulting in a significant reduction of clarithromycin MIC by 4–8 fold.53

In the cases of *M. abscessus*, BER exhibited the ability to decrease the MIC of clarithromycin and linezolid by 4-fold (from 0.5 to 0.125 μg/mL) and 8-fold (from 32 to 4 μg/mL), respectively (Tables 1 and S3).54 The combination of BER reversed linezolid resistance to susceptibility. Additionally, when combined with 1/2 MIC BER, the MICs of *M. abscessus* to other antibiotics could also be reduced, such as methoxybenzyl/pyrimethamine, amikacin, tigecycline, imipenem, ceftazidime and ciprofloxacin. However, no significant effect was observed in the combination with tigecycline, doxycycline, minocycline, ceftazidime, amoxicillin and moxifloxacin.54 These results indicated that BER enhances the bacteriostatic effects of certain antibiotics and could offer new therapeutic options for the treatment of NTM infections.

**Mechanism of the Synergistic Effect of Berberine**

Antibiotic adjuvants were classified into two distinct groups based on their intended target, namely Class I agents that act on the pathogen, and Class II agents that act on the host.32 BER functioned as a dual adjuvant and exhibited both Class I and Class II adjuvant activities. On the one hand, it reduced the development of antibiotic resistance by inhibiting bacterial efflux pumping and biofilm formation. On the other hand, it interacted with host defense mechanisms and restored the host’s gut microbiota to augment the action of antibiotics.

**Action on the Pathogens as Class I Adjuvant**

**Inhibition of Antibiotic Efflux**

Efflux pumps were transmembrane proteins that facilitate the transportation of a diverse range of toxic compounds, including antibiotics, across bacterial membranes in an energy-dependent manner.66 The majority of efflux systems were capable of transporting multiple unrelated substances, thereby potentially contributing to multidrug resistance.4 This form of resistance primarily impacted antibiotics impeding protein and DNA biosynthesis within the cell, particularly macrolides, tetracyclines and fluoroquinolones.6

BER impeded the efflux of antibiotics through direct inhibition of the expression of efflux pump genes or competition with the binding sites of efflux pump substrates. The reduction in efflux raised the concentration of antibiotics in bacteria and reduced the incidence of drug resistance. Recent studies have identified that BER primarily targets the MexXY efflux pump, including MexXY-like or MexXY-dependent efflux pumps.41–43 By inhibiting efflux systems, BER resulted in a reduction in MexXY-dependent resistance to aminoglycosides in *P. aeruginosa*, *Acinetobacter xylosoxidans* and *Burkholderia cepacia* (Figure 2A). This effect was also observed for other classes of antibiotics, such as cephalosporins (cefépime), macrolides (erythromycin) and lincosamides (lincomycin).51 Additionally, the inhibition of the MexXY-OprM efflux pump system by BER caused imipenem-resistant *P. aeruginosa* to re-sensitize to the drug. The combination of BER and imipenem significantly reduced the expression of *mexX*, *mexY*, *mexZ* and *oprM*.44

On the other hand, BER, as an amphoteric cation, was a preferable efflux substrate for certain MDR bacteria.67 The combination of BER could diminish the efflux of other antibiotics and maintain their concentrations in cells since BER was pumped out first (Figure 2B). In the treatment of *A. baumannii*, BER was more likely a pump competitor to restore antibiotic sensitivity than an inhibitor. It significantly enhanced the expression of the AdeABC efflux pump gene *adeB* and exhibited a greater affinity than antibiotics.45 In MDR *P. aeruginosa*, BER upregulated the expression of genes *acrA*,...
acrB, tolC and acrR associated with the AcrAB-TolC efflux pump, ultimately expanding the antimicrobial efficacy of ciprofloxacin against this bacterium.47

Inhibition of Biofilm Formation

Biofilms are a microbial community enmeshed in a self-generated matrix of extracellular polymeric substances (EPS) and attached to either biotic or abiotic surfaces.68 Compared to planktonic ones, bacteria within biofilms exhibit greater resistance (10–1000 times) to sanitizers and disinfectants.69 This resistance is attributed to the reduction of permeability, the decrease of target expression caused by reduced metabolic activity, and the production of large numbers of persisters.66 Inhibiting biofilm formation has been found to have a noteworthy impact on the reversal of bacterial resistance.70

BER, when used in combination with certain antibiotics, has demonstrated the ability to impede biofilm formation in corresponding bacteria. The combination of BER and fusidic acid, clindamycin and rifampicin prevented the formation of MRSA biofilm and disrupted the biofilm completion;70,71 the combination of BER with azithromycin inhibited P. aeruginosa biofilm formation;40,71 and the combination of BER with linezolid reduced the biofilm formation in M. abscessus.54

BER has the potential to inhibit biofilm formation at multiple stages, including bacterial attachment, microcolony formation, biofilm maturation and biofilm dispersal.72 It can impact the expression of the type I fimbriae gene fimA in S. typhimurium, resulting in reduced quantities of type I fimbriae and consequently decreasing bacterial activity and adhesion (Figure 3A).73 BER can reduce the formation of Salmonella biofilms by 31.20%.74 It interacts with the quorum-sensing receptors LasR and RhlR in P. aeruginosa, effectively inhibiting the formation and maturation of biofilms (Figure 3B).74 The combination of BER and azithromycin has been shown to significantly reduce the levels of QS molecules in P. aeruginosa, as well as the expression of key genes involved in biofilm establishment and structural stability, such as lasI, lasR, rhlI, rhlR, eDNA68 and the alginate-related regulatory genes algG, algD and algR.71 BER reduced the relative expression levels of biofilm-related genes (sarA, fnbA, rbf, eno, lrgA, strA, cidA and agr) in S. aureus, consequently impacting biofilm formation at stages including bacterial attachment, aggregation, structural maturation and dispersal (Figure 3C).75–77 These findings highlight the potential of BER as a promising therapeutic agent for the prevention and treatment of biofilm-associated infections.
Other Mechanisms of Action on Pathogens

BER has been observed to potentially exhibit synergistic antibacterial effects through additional mechanisms, such as the increase of cell membrane permeability and the disruption of the bacterial cell wall and cytoplasmic membrane. In an alkaline pH environment, BER enhanced bacterial cell membrane permeability and disrupted the proton motive force, implying a potential mechanism by which it can synergistically interact with other antibacterial compounds under milder conditions.\(^{78,79}\) It has been demonstrated that the presence of BER facilitates the intracellular penetration of antibiotics such as clindamycin and levofloxacin in MRSA, leading to an increase in drug concentration within the bacteria and subsequent antibacterial activity. This phenomenon may be attributed to the ability of BER to compromise the structural integrity of the bacterial cell wall and membrane in MRSA,\(^{50}\) but further evidence is required.

Action on the Host as Class II Adjuvants

BER has the potential to augment the effectiveness of antibiotics in the host through two ways, by modulating host immunity or by restoring the host’s gut microbiota to modulate its inflammatory response to infection. For example, when utilized in combination with rifampicin and isoniazid, BER enhanced the efficacy of antituberculosis treatment by modulating the host’s immune status.\(^{50}\) When used as an adjuvant therapy in a mouse model of pulmonary TB, BER mitigated pulmonary inflammation by selectively targeting immune cell
recruitment and reducing inflammatory cytokines, while avoiding the induction of granulomatous lung pathology or caseous necrosis. In the P. aeruginosa infection models, the administration of 0.8 mg/kg of azithromycin in combination with 3.2 mg/kg of BER resulted in a significant increase in the mice survival, notable improvements in lung inflammation, reduced levels of IL-6 and IL-8, and increased levels of IL-10.

Additionally, BER has the ability to reverse both the structural and quantitative changes of the gut microbiota in pathological conditions. It eliminates harmful bacteria in the intestines while enhancing the composition of beneficial bacteria, including Bifidobacterium adolescentis and Lactobacillus acidophilus. There were two main ways in which the gut microbiota interacts directly with BER: BER regulates the gut microbiota, and the gut microbiota transforms BER. The reported function of BER as a Class II adjuvant was mainly attributed to the former, such as restoring the imbalance in bacterial communities caused by vancomycin through the modulation of the structure and quantity of the gut microbiota, effectively preventing the recurrence of C. difficile infection.

**Conclusion**

BER, as an antibiotic adjuvant, can reduce the resistance of many notoriously MDR bacteria to specific antibiotics and even reverse their resistance phenotypes. The combination with BER resulted in an enhanced antibacterial effect of many antibiotics, including β-lactams (sulbactam, meropenem, oxacillin and imipenem), quinolones (ciprofloxacin and levofloxacin), aminoglycosides (amikacin, arbekacin and gentamicin), tetracyclines (tigecycline), rifamycins (rifampicin), macrolides (clarithromycin and azithromycin), lincosamides (clindamycin), and fusidic acid. This offers novel perspectives for the treatment of prevalent MDR gram-negative bacteria (P. aeruginosa, A. baumannii, Salmonella and K. pneumoniae), gram-positive bacteria (MRSA and C. difficile), and mycobacteria (M. abscessus and M. avium). The known mechanisms by which BER augments the bactericidal efficacy of antibiotics include mitigation of antibiotic efflux, inhibition of biofilm formation, and regulation of host immunity and gut microbiota. The genes implicated in these mechanisms comprise those associated with the AdeABC efflux pump (adeB), MexXY efflux pump (mexX, mexY, mexZ and oprM), QS system (lasI, lasR, rhlI and rhlR), and biofilm components (algG, algD and algR).

There were limitations in the current studies on BER as an antibiotic adjuvant, such as the incomplete and unsystematic design of the combination drug susceptibility experiments, and the lack of mechanistic studies. The limited sample sizes and exclusive focus on a single antibiotic or antibiotic class hinder the comprehensive assessment of the collective synergistic effects of BER with commonly used therapeutic antibiotics on the targeted multidrug-resistant bacteria. The precise mechanisms underlying the adjuvant function of BER have yet to be fully elucidated through mechanistic studies. For example, it remains unclear whether the disparity in the synergistic effect of BER between the rrs A2059C mutant strain of M. avium and the wild-type strain. Moreover, the utilization of BER in conjunction with antibiotics for the treatment of MDR bacterial infections poses several obstacles, such as the feasibility of achieving a synergistic effect in vivo. The solution to this predicament entails consideration of intricate pharmacology, pharmacokinetics, and in vivo drug metabolism, among other pivotal determinants. This suggests that prior to clinical trials, it is imperative to conduct a thorough toxicological evaluation. Despite the challenges and complexities, these attempts are worthwhile owing to BER’s offering a new strategy in addressing MDR bacterial infections amidst limited antibiotic development and the continued rise of drug resistance.

**Acknowledgments**

This study was supported by Project of Hangzhou Municipal Health Commission (A20210201).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


